Fig. 1

Osimertinib activated AXL in EGFR-mutated NSCLC cells in vitro. a Human tyrosine kinase phosphorylation array analysis of PC-9 cells in the presence or absence of osimertinib (100 nmol/L) for 72 h. b PC-9 cells were treated with osimertinib (100 nmol/L), lysed, and the indicated proteins detected by western blotting. c Nonspecific siRNA control, specific siRNA for AXL, HER3 or MET introduced into the indicated cells. After 24 h, the cells were incubated with or without osimertinib (100 nmol/L) for 72 h and cell viability was determined using MTT assays. *P < 0.05 for comparisons of osimertinib-treated cells with parental cells treated with nonspecific control siRNA. Comparisons by paired Student’s t tests. d PC-9 cells were treated for 72 h with the indicated siRNAs, or combinations of the indicated siRNAs and cell viability was determined using MTT assays. *P < 0.05 compared with the respective parental cells. Comparisons by paired Student’s t tests. e The indicated siRNAs were introduced into PC-9 cells. After 24 h, the cells were incubated with or without osimertinib (100 nmol/L) for 72 h and lysed, and the indicated proteins detected by western blotting. f Cell lines were treated with or without osimertinib (100 nmol/L) for 72 h. The cells were lysed and the indicated proteins were detected by western blotting with immunoprecipitation of the indicated proteins